Non-small Cell Lung Cancer Clinical Trials

863 recruitingLast updated: June 17, 2026

There are 863 actively recruiting non-small cell lung cancer clinical trials across 73 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Non-small Cell Lung Cancer Trials at a Glance

863 actively recruiting trials for non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 73 countries. The largest study group is Phase 2 with 379 trials, with the heaviest enrollment activity in Houston, New York, and Guangzhou. Lead sponsors running non-small cell lung cancer studies include AstraZeneca, Hunan Province Tumor Hospital, and Sun Yat-sen University.

Browse non-small cell lung cancer trials by phase

Treatments under study

About Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer? There are currently 583 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 863 trials

Recruiting
Phase 2

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced/Metastatic Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals300 enrolled10 locationsNCT07154290
Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

ALK-Positive Lung CancerALK-positive Non-small Cell Lung CancerALK-positive NSCLC
TRIANA Biomedicines, Inc.160 enrolled9 locationsNCT07491497
Recruiting
Phase 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Non-small Cell Lung Cancer
AstraZeneca675 enrolled283 locationsNCT06357533
Recruiting

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

Non-small Cell Lung Cancer
AstraZeneca590 enrolled1 locationNCT07413757
Recruiting

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
N-Power Medicine130 enrolled8 locationsNCT07028489
Recruiting

An External Control Arm Study in Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
N-Power Medicine650 enrolled8 locationsNCT07174388
Recruiting
Phase 3

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled200 locationsNCT07195695
Recruiting
Not Applicable

Hybrid Prehabilitation Before Thoracic Surgery

Non-small Cell Lung Cancer
ADIR Association38 enrolled1 locationNCT06866717
Recruiting
Phase 1Phase 2

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Non-small Cell Lung Cancer
Hoffmann-La Roche320 enrolled71 locationsNCT05789082
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Not Applicable

A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

Non-small Cell Lung Cancer
AstraZeneca1,000 enrolled2 locationsNCT07613424
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 3

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 2

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

Non-small Cell Lung CancerMetastatic Lung Cancer
University of Chicago39 enrolled1 locationNCT07603856
Recruiting
Phase 3

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled212 locationsNCT06422143
Recruiting
Phase 2

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non-small Cell Lung Cancer
University of Alabama at Birmingham24 enrolled1 locationNCT06364917
Recruiting
Phase 3

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC868 enrolled229 locationsNCT06077760
Recruiting
Phase 3

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled225 locationsNCT06345729